Comparative Pharmacology
Head-to-head clinical analysis: OPANA ER versus PALLADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPANA ER versus PALLADONE.
OPANA ER vs PALLADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Opana ER (oxymorphone hydrochloride) is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action is analgesia via activation of mu-opioid receptors in the central nervous system, leading to altered perception and response to pain.
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
Initial: 5 mg orally every 12 hours; titrate by 5-10 mg every 12 hours every 3-7 days; maximum 40 mg every 12 hours.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
None Documented
None Documented
Terminal elimination half-life: 11.1–13.8 hours; clinically relevant as steady-state achieved in 2–3 days
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Renal (primarily as glucuronide conjugates and unchanged drug): 85-90%; Fecal: <10%
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Category C
Category C
Opioid Analgesic
Opioid Analgesic